Zheng Feng

Director & Head, Clinical Genomics, Clinical Biomarker Technologies EMD Serono, the Healthcare business of Merck KGaA, Darmstadt, Germany

Seminars

Wednesday 7th October 2026
Panel Discussion: Transforming Patient Monitoring Through Innovation in Liquid Biopsy Analytes, Detection Sensitivity & Data Interpretation
12:50 pm
  • What are the most impactful recent innovations in liquid biopsy biomarkers, and how can these be robustly validated and effectively integrated into clinical trial designs?
  • How can drug-diagnostic stakeholders build high-value, collaborative frameworks to advance liquid biopsy technologies, particularly in improving detection sensitivity, standardization, and data interpretation?
Wednesday 7th October 2026
Definition of the Best Practices in Clinical Utility of Liquid Biopsy: Clinical Guideline, Technologies, Cost-Effectiveness, Reimbursement, a Unidirectional or Multidirectional Path
11:50 am
  • Decipher the tumor shedding mechanism
  • Precision medicine-driven cut-off strategy implmentation
  • Tired fit-for-purpose liquid biopsy solutions combined with real-world genomic data mining
  • 1ctDNA-guided treatment and consideration of cost-effectiveness thresholds
Zheng_Feng[1]
View all Speakers
View Event Brochure